Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jun;27(3):129-35.
doi: 10.1023/a:1023865727780.

Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reactions

Affiliations

Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reactions

Mi-Sun Kim et al. Inflammation. 2003 Jun.

Abstract

Mast cells are key as effector cells in the early phase allergic inflammation and in diverse immunological and pathological processes. Forsythia fructus (F. fructus) has used as a traditional medicine for inflammatory diseases. In the present study, we determined the effect of F. fructus extracts on compound 48/80-induced paw oedema and vascular permeability in vivo. In addition, we investigated in vitro whether F. fructus has inhibitory effects on compound 48/80-induced histamine releases from rat peritoneal mast cells (RPMC), and on phorbol 12-myristate 13-acetate (PMA) plus A23187-induced tumor necrosis factor-alpha (TNF-alpha) releases from human mast cells (HMC-1). In mice orally administrered F. fructus (100 microg/g) for 1 h, compound-48/80-induced oedema and vascular permeability were significantly reduced rather than those receiving intravenous injection of ketotifen, mast cell stabilizer. F. fructus dose-dependently inhibited the histamine release induced by compound 48/80 from RPMCs. Moreover, F. fructus had no cytotoxic effects on cell viability and had inhibitory effects on TNF-alpha secretion from HMC-1. These results suggest that F. fructus is a potential herb medicine for treatment of inflammatory diseases through downmodulating mast cell activation.

PubMed Disclaimer

References

    1. Eur J Pharmacol. 2000 Apr 21;395(1):47-50 - PubMed
    1. Clin Exp Allergy. 2000 Sep;30(9):1205-12 - PubMed
    1. Eur J Pharmacol. 1997 Jul 23;331(2-3):237-43 - PubMed
    1. Inflamm Res. 2000 Jul;49(7):355-60 - PubMed
    1. Br J Pharmacol. 1998 Oct;125(3):419-22 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources